Table 2.
Patient and tumor characteristics for ER and PR status independently. Data expressed as n (%) unless otherwise specified
| ER Low n = 78 | ER Intermediate n = 107 | ER High n = 522 |
P value | PR Low n = 229 |
PR High n = 478 |
P value | |
|---|---|---|---|---|---|---|---|
| Age (years) | 56.6 | 56.7 | 60.6 | 0.0006 | 63.6 | 57.6 | < 0.0001 |
| BMI | |||||||
| 18.5–24 | 52.4 | 54.3 | 51.0 | 0.107 | 50.0 | 52.4 | 0.763 |
| 25–29 | 30.2 | 35.1 | 26.8 | 30.2 | 27.5 | ||
| ≥30 | 17.5 | 10.6 | 22.2 | 19.8 | 20.1 | ||
| Overall stage | |||||||
| 1 | 52 (67.5) | 69 (65.1) | 315 (62.1) | 0.514 | 137 (62.3) | 299 63.6) | 0.018 |
| 2 | 20 (26.0) | 23 (21.7) | 125 (24.7) | 45 (20.5) | 123 (26.2) | ||
| 3 | 5 (6.5) | 14 (13.2) | 67 (13.2) | 38 (17.3) | 48 (10.2) | ||
| Tumor grade | |||||||
| 1 | 32 (41.6) | 31 (29.8) | 126 (24.5) | 0.03 | 59 (26.6) | 130 (27.5) | 0.113 |
| 2 | 41 (53.3) | 69 (66.4) | 363 (70.6) | 147 (66.2) | 326 (68.9) | ||
| 3 | 4 (5.2) | 4 (3.9) | 25 (4.9) | 16 (7.2) | 17 (3.6) | ||
| Receptor subtype | |||||||
| ER + PR + HER2- | 47 (8.2) | 77 (13.5) | 448 (78.3) | < 0.001 | 126 (22.0) | 446 (78.0) | < 0.001 |
| ER + PR-HER2- | 16 (21.1) | 14 (18.4) | 46 (60.5) | 76 (100.0) | 0 (0.0) | ||
| HER2 + | 7 (22.6) | 9 (29.1) | 15 (48.4) | 16 (51.6) | 15 (48.4) | ||
| High Ki67 (> 14%) | 6 (33.3) | 16 (42.1) | 117 (38.7) | 0.818 | 47 (32.9) | 96 (67.1) | 0.615 |
| Presence of LVI | 6 (8.1) | 8 (7.8) | 24 (4.7) | 0.282 | 17 (7.8) | 21 (4.5) | 0.080 |
| Presence of LCIS | 50 (65.8) | 66 (63.5) | 371 (72.8) | 0.104 | 137 (62.6) | 350 (74.3) | 0.002 |
| Type of treatment | |||||||
| Lumpectomy | 14 (17.9) | 20 (18.7) | 86 (16.8) | 0.790 | 50 (22.4) | 70 (14.7) | 0.044 |
| Lumpectomy + rad | 21 (26.9) | 35 (32.7) | 183 (35.7) | 69 (30.9) | 170 (35.8) | ||
| Mastectomy | 30 (38.5) | 35 (32.7) | 176 (34.3) | 69 (30.9) | 172 (36.2) | ||
| Mastectomy + rad | 13 (16.7) | 17 (15.9) | 68 (13.3) | 35 (15.7) | 63 (13.3) | ||
| Neoadj chemotherapy | 19 (24.7) | 18 (18.9) | 48 (10.5) | 0.001 | 36 (17.4) | 49 (11.6) | 0.048 |
| Adj chemotherapy | 51(65.8) | 83 (77.1) | 425 (81.4) | 0.007 | 63 (28.4) | 108 (22.9) | 0.117 |
N(%)
BMI body mass index; ER Estrogen receptor; PR progesterone receptor; LVI lymphovascular invasion; LCIS lobular carcinoma in situ; HER2 Human Epithelial Growth Factor Receptor-2; ILC invasive lobular carcinoma; Neg negative; Rad radiation; Neoadj neoadjuvant; Adj adjuvant